Service Facility

The Enzyre Service Facility provides consultancy and laboratory services in the area of blood coagulation, hemostasis, thrombosis and immunogenicity testing for blood coagulation factors. Our services are available for pharmaceutical and diagnostic companies, hospitals, insurance organizations and other academic clinical or laboratory departments from international institutes. Our service facility applies the highest quality standards and works together with dedicated scientific staff and supportive team members. 

(Micro) Global assays

Global assays are a new class of coagulation assays measuring one parameter in response to the total coagulation cascade. Global assays are an essential tool for in-depth analysis of blood coagulation, fibrinolysis and its interplay. With the capacity to measure thrombin and plasmin generation using our previously developed Novel Hemostasis Assay 1,2 or the recently developed micro thrombin and plasmin generation (maximum 20 µl of blood plasma) multiple parameters will be derived in just one plasma sample. Global haemostasis assays appear to be useful in evaluating overall haemostatic capacity both in the hemorrhagic or thrombotic field. Moreover, thrombin and plasmin generation is a powerful technology with a wide variety of applications in pharmaceutical development and clinical research. With our long history in global assay research, we have extensive experience to perform dedicated functional testing of pharmaceutical products. 

Micro coagulation factor assays

Accurate coagulation factor testing is imperative in clinical practice and in pharmaceutical research and development activities to bring novel coagulation therapies to market. In addition to the micro global assays Enzyre developed micro quantitative coagulation assays for coagulation factors or anticoagulants like the novel class of Direct Oral AntiCoagulants (DOACs) and other inhibitors 3,4. Our excellent mode of operation allows fast, precise and reliable measurements of coagulation factor activity testing for our customers.

(Micro) Pharmacokinetic and -dynamic analysis services

When you outsource your PK/PD analyses to Enzyre Service Facility, you get more than just a service organization: you get access to the best minds in science. With more than 25 years of experience in laboratory services we'll deliver fast and top-level results. Pharmacokinetic /-dynamics (PK/PD) analysis of coagulation factors requires different solutions from those traditionally employed in the analysis of pharmaceuticals. We have experience in the development and validation of PK/PD assays for the measurement of coagulation factors even in small volume pediatric samples 5,6.

Exploratory biomarker services

Developing novel biomarker assays requires a great deal of time, a high level of expertise, and often comes with high expenses. We offer consultancy and services for biomarker discovery, validation and assay development in plasma and also derivatives of blood, such as saliva 7,8. With ample experience Enzyre Service Facility provides technical expertise, a high quality standard and a comprehensive approach for your preclinical or clinical stage sample analysis.

External quality control

To assess our quality we participate in the external quality control of the ECAT foundation for the services we offer. We participate in the program for the one-stage factor VIII, chromogenic factor VIII and thrombin generation assay.

  • 1. Geffen, M. Van et al. A novel hemostasis assay for the simultaneous measurement of coagulation and fibrinolysis. Hematology 16, 327–36 (2011).
  • 2. Van Geffen, M. & Van Heerde, W. L. Global haemostasis assays, from bench to bedside. Thrombosis Research 129, 681–687 (2012).
  • 3. Verbruggen, B., Meijer, P., Novákova, I. & Van Heerde, W. Diagnosis of factor VIII deficiency. Haemophilia 14, 76–82 (2008).
  • 4. Dardikh, M. et al. Low-titre inhibitors, undetectable by the Nijmegen assay, reduce factor VIII half-life after immune tolerance induction. Journal of Thrombosis and Haemostasis 10, 706–708 (2012).
  • 5. Van Geffen, M. et al. Pharmacodynamics of recombinant activated factor VII and plasma-derived factor VII in a cohort of severe FVII deficient patients. Thromb. Res. 132, 116–122 (2013).
  • 6. Mathijssen, N. C. J. et al. Increased volume of distribution for recombinant activated factor VII and longer plasma-derived factor VII half-life may explain their long lasting prophylactic effect. Thromb. Res. 132, 256–262 (2013).
  • 7. Harthoorn, L. F. et al. Salivary biomarkers associated with perceived satiety and body mass in humans. Proteomics - Clin. Appl. 1, 1637–1650 (2007).
  • 8. Schipper, R. et al. SELDI-TOF-MS of saliva: Methodology and pre-treatment effects. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 847, 45–53 (2007).
  • Dit e-mailadres wordt beveiligd tegen spambots. JavaScript dient ingeschakeld te zijn om het te bekijken.
Enzyre BV
  • Transistorweg 5
  • 6534-AT Nijmegen
  • The Netherlands
  • Dit e-mailadres wordt beveiligd tegen spambots. JavaScript dient ingeschakeld te zijn om het te bekijken.
Follow us